Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 752

Similar articles for PubMed (Select 18771987)

1.

Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markers.

Dugoff L, Cuckle HS, Hobbins JC, Malone FD, Belfort MA, Nyberg DA, Comstock CH, Saade GR, Eddleman KA, Dar P, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME; FaSTER Trial Research Consortium.

Am J Obstet Gynecol. 2008 Sep;199(3):290.e1-6. doi: 10.1016/j.ajog.2008.06.099.

PMID:
18771987
2.

Obstetrical complications associated with abnormal maternal serum markers analytes.

Gagnon A, Wilson RD, Audibert F, Allen VM, Blight C, Brock JA, D├ęsilets VA, Johnson JA, Langlois S, Summers A, Wyatt P; Society of Obstetricians and Gynaecologists of Canada Genetics Committee.

J Obstet Gynaecol Can. 2008 Oct;30(10):918-49. Review. English, French.

PMID:
19038077
3.

Practical strategies in contingent sequential screening for Down syndrome.

Benn P, Wright D, Cuckle H.

Prenat Diagn. 2005 Aug;25(8):645-52.

PMID:
16049988
4.

Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.

Kagan KO, Wright D, Baker A, Sahota D, Nicolaides KH.

Ultrasound Obstet Gynecol. 2008 Jun;31(6):618-24. doi: 10.1002/uog.5331.

5.

Prediction of adverse pregnancy outcomes by combinations of first and second trimester biochemistry markers used in the routine prenatal screening of Down syndrome.

Huang T, Hoffman B, Meschino W, Kingdom J, Okun N.

Prenat Diagn. 2010 May;30(5):471-7. doi: 10.1002/pd.2505.

PMID:
20440736
6.
7.

First trimester predictors of adverse pregnancy outcomes.

Brameld KJ, Dickinson JE, O'Leary P, Bower C, Goldblatt J, Hewitt B, Murch A, Stock R.

Aust N Z J Obstet Gynaecol. 2008 Dec;48(6):529-35. doi: 10.1111/j.1479-828X.2008.00912.x.

PMID:
19133038
8.

Combined second-trimester biochemical and ultrasound screening for Down syndrome.

Benn PA, Kaminsky LM, Ying J, Borgida AF, Egan JF.

Obstet Gynecol. 2002 Dec;100(6):1168-76.

PMID:
12468159
9.

First- and second-trimester screening: detection of aneuploidies other than Down syndrome.

Breathnach FM, Malone FD, Lambert-Messerlian G, Cuckle HS, Porter TF, Nyberg DA, Comstock CH, Saade GR, Berkowitz RL, Klugman S, Dugoff L, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, Tripp T, Bianchi DW, D'Alton ME; First and Second Trimester Evaluation of Risk (FASTER) Research Consortium.

Obstet Gynecol. 2007 Sep;110(3):651-7.

PMID:
17766613
10.

Sensitivity and specificity of screening for Down syndrome with alpha-fetoprotein, hCG, unconjugated estriol, and maternal age.

MacDonald ML, Wagner RM, Slotnick RN.

Obstet Gynecol. 1991 Jan;77(1):63-8. Erratum in: Obstet Gynecol 1991 May;77(3):462.

PMID:
1701526
11.

Predicting the result of additional second-trimester markers from a woman's first-trimester marker profile: a new concept in Down syndrome screening.

Maymon R, Cuckle H, Jones R, Reish O, Sharony R, Herman A.

Prenat Diagn. 2005 Dec;25(12):1102-6.

PMID:
16231324
12.

Maternal serum-integrated screening for trisomy 18 using both first- and second-trimester markers.

Palomaki GE, Neveux LM, Knight GJ, Haddow JE.

Prenat Diagn. 2003 Mar;23(3):243-7.

PMID:
12627428
13.

New Down syndrome screening algorithm: ultrasonographic biometry and multiple serum markers combined with maternal age.

Bahado-Singh RO, Oz AU, Kovanci E, Deren O, Copel J, Baumgarten A, Mahoney J.

Am J Obstet Gynecol. 1998 Dec;179(6 Pt 1):1627-31.

PMID:
9855608
14.

A novel method for the detection of Down syndrome with the use of four serum markers.

Azuma M, Yamamoto R, Wakui Y, Minobe S, Satomura S, Fujimoto S.

Am J Obstet Gynecol. 2002 Jul;187(1):197-201.

PMID:
12114910
15.

The identification of risk of spontaneous fetal loss through second-trimester maternal serum screening.

Huang T, Owolabi T, Summers AM, Meier C, Wyatt PR.

Am J Obstet Gynecol. 2005 Aug;193(2):395-403.

PMID:
16098861
16.

Quad screen as a predictor of adverse pregnancy outcome.

Dugoff L, Hobbins JC, Malone FD, Vidaver J, Sullivan L, Canick JA, Lambert-Messerlian GM, Porter TF, Luthy DA, Comstock CH, Saade G, Eddleman K, Merkatz IR, Craigo SD, Timor-Tritsch IE, Carr SR, Wolfe HM, D'Alton ME; FASTER Trial Research Consortium.

Obstet Gynecol. 2005 Aug;106(2):260-7.

PMID:
16055573
17.

Biochemical screening for Down syndrome.

Cuckle H.

Eur J Obstet Gynecol Reprod Biol. 2000 Sep;92(1):97-101. Review.

PMID:
10986441
18.
19.

Predicting risk of preterm delivery by second-trimester measurement of maternal plasma corticotropin-releasing hormone and alpha-fetoprotein concentrations.

McLean M, Bisits A, Davies J, Walters W, Hackshaw A, De Voss K, Smith R.

Am J Obstet Gynecol. 1999 Jul;181(1):207-15.

PMID:
10411821
20.

Efficacy of screening for fetal Down syndrome in the United States from 1974 to 1997.

Egan JF, Benn P, Borgida AF, Rodis JF, Campbell WA, Vintzileos AM.

Obstet Gynecol. 2000 Dec;96(6):979-85.

PMID:
11084189
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk